

REMARKS

The above-identified application was allowed in the Office Action mailed August 11, 2008. The issue fee has not been paid.

On October 21, 2008, subsequent to the receipt of the Notice of Allowance dated August 11, 2008, we received a phone call from Ms. Sharon Hurt, the Examiner of this application. The Examiner requested submission of page 33, missing from the file, of the English language translation of the International Application as filed. The requested amendment is submitted to fulfill the Examiner's request, adding the missing text of page 33 to the specification of this application.

This application is a National Stage (§ 371) application of International Application No. PCT/EP04/06516. The description of page 33 provided herein appears in the German language publication of the PCT application (WO 2004/113370), on page 25, but is, according to the Office, missing from the English language translation of the PCT application previously filed in this application.

Applicants enclose a copy of translated page 33, as well, as a courtesy for the Office. Applicants further note that this original page was amended in the Preliminary Amendment filed on December 20, 2005. Therefore, the text on page 2-3 includes the amendment from the Preliminary Amendment, whereas the attached page 33 contains the original translation (prior to the amendment). This Preliminary Amendment served to correct a minor typographical error (changed the duplicate/out of order 99% to 96%).

In view of these circumstances, applicants respectfully submit that entry of this amendment is proper and courteously request that the amendment be timely entered. The requested amendments are fully supported by the specification and drawings, will not require an additional search, and does not raise new issues.

Please kindly indicate acceptance of this amendment as soon as possible.
Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 3, 2008

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796
(202) 408-4086

SEQ ID NO:24

117 N R G Q C 121

SEQ ID NO:25

118 R G Q C K 122

SEQ ID NO:26

114 A I N N R G Q 120

SEQ ID NO:27

114 A I N N R G Q C K 122

SEQ ID NO:28

114 A I N N R G Q C K T C T T T A H 129

SEQ ID NO:29.

114 A I N N R G Q C K T C T T T A H G T S M
Y P Y C C C T 140

SEQ ID NO:30

121 C K T C T T T A H G T S M Y P Y C C C T 140.

(12) An oligopeptide or polypeptide according to (10)
or (11) which is in each case at least 65% or 66%
5 or 67% or 68% or 69% or 70% or 71% or 72% or 73%
or 74% or 75% or 76% or 77% or 78% or 79% or 80%
or 81% or 82% or 83% or 84% or 85% or 86% or 87%
or 88% or 89% or 90% or 91% or 92% or 93% or 94%
or 95% or 99% or 97% or 98% or 99% identical with
10 one of the sequences selected from the group
consisting of SEQ ID NO: 12 to SEQ ID NO: 30.

(13) An isolated polypeptide corresponding to the
sequence of the HBs antigen of the hepatitis B
15 virus, characterized in that it contains an
oligopeptide or polypeptide according to one of
the subject-matter items (10) to (12).

(14) A fragment of a polypeptide which corresponds to
20 the sequence of the HBs antigen of the hepatitis B